Yazar "Arat, Mutlu" için listeleme
-
Comparison of outcomes of total body irradiation (TBI) vs non-TBI conditioning regimens in acute lymphoblastic leukemia for allogeneic transplantation
Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Özçelik, Tülay; Arat, Mutlu; Hindilerden, İpek Yonal; Beşışık, Sevgi Kalayoğlu; Nalcacı, Meliha; Uzay, Ant; Kartı, Süleyman Sami; Kıvanç, Demet; Sargın, Deniz (Nature Publishing Group, 2019)... -
Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)
Tekgündüz, Emre; Demirkan, Fatih; Vural, Filiz; Göker, Hakan; Özdoğu, Hakan; Kiki, İlhami; Aydoğdu, İsmet; Kaynar, Leylagül; Erkurt, Mehmet Ali; Çağırgan, Seçkin; Beşışık, Sevgi; Dağdaş, Simten; Koca, Ebru; Kadıköylü, Gürhan; Gündüz, Eren; Yılmaz, Mehmet; Beköz, Hüseyin; Ural, Ali Uğur; Baştürk, Abdulkadir; Arat, Mutlu; Albayrak, Murat; Öztürk, Erman; Akyol, Alev; Bolaman, Ali Zahit; Nevruz, Oral; Özkan, Hasan Atilla; Özgür, Gökhan; Altuntaş, Fevzi (Pergamon-Elsevier Science Ltd., 2017)Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in ... -
HLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers
Beksaç, Meral; Savran Oğuz, Fatma; Topçuoğlu, Pervin; Karasu, Gülsun; Arat, Mutlu; Aksoylar, Serap; Kansoy, Savaş; Kalayoğlu Beşışık, Sevgi; Küpesiz, Alphan; Hazar, Volkan; Altuntaş, Fevzi; Ünal, Ali; Gülbaş, Zafer; Sargın, Fatma Deniz; İlhan, Osman; Gürman, Günhan; Yeşilipek, Akif (Nature Publishing Group, 2015)Introduction: Hematopoietic stem cell transplantation (HSCT) from an unrelated donor has been established as an effective treatment option for patients with hematological diseases who lack a human leukocyte antigen ... -
Nivolumab for relapsed or refractory hodgkin lymphoma experience in Turkey
Ferhanoğlu, Burhan; Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Gülbaş, Zafer; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Tekgündüz, Emre; Kaya, Ali Hakan; Taştemir, N.; Arat, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abalı, Hüseyin; Turgut, Mehmet; Kaynar, Leylagül; Karadoğan, İhsan; Özbalak, Murat; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Yıldırım, Rahsan; Barışta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Yüksel, Meltem Kurt; Sönmez, Mehmet; Toprak, Selami Koçak (Ferrata Storti Foundation, 2017)… -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin; Özbalak, Murat; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Altuntaş, Fevzi; Kızıl Çakar, Merih; Sönmez, Mehmet; Gülbaş, Zafer; Demir, Nazlı; Kaynar, Leylagül; Yıldırım, Rahşan; Karadoğan, İhsan; Arat, Mutlu; Kapucu, İrem; Alayvaz Aslan, Nevin; Özkocaman, Vildan; Turgut, Mehmet; Kurt Yüksel, Meltem; Özcan, Muhit; Kabukçu Hacıoğlu, Sibel; Barışta, İbrahim; Demirkaya, Metin; Saydam, Güray; Toprak, Selami Koçak; Yılmaz, Mehmet; Demirkol, Onur; Ferhanoğlu, Burhan (Springer, 2020)Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved ... -
Preliminary report of the academic CAR-T (ISIKOK-19) cell clinical trial in Turkey: Characterization of product and outcomes of clinical application
Erdoğan, Ebru; Yalçın, Koray; Hemşinlioğlu, Cansu; Sezgin, Aslıhan; Seyis, Utku; Kançağı, Derya Dilek; Taştan, Cihan; Yurtsever, Bulut; Turan, Raife Dilek; Çakırsoy, Didem; Abanuz, Selen; Sır Karakuş, Gözde; Elek, Muhammer; Beköz, Hüseyin Saffet; Gemici, Aliihsan; Sargın, Deniz; Arat, Mutlu; Ferhanoğlu, Burhan; Pekgüç, Ebru; Örnek, Serdar; Büyüktaş, Deram; Birgen, Nur; Ratip, Siret; Ovalı, Ercüment (Turkish Society of Hematology, 2022)Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products ...